The FDA issued a Class I recall on blood kits made by Hospira (NYSE:HSP) after the medical device company reported that at least 1 patient’s death was partially due to a delay in treatment caused by a punctured blood bag.
Hospira Inc.
Hospira bounces back in Q2, gains Wall Street’s favor
MassDevice.com Q&A: Monarch Medical CEO Dr. Wilson Constantine
Monarch Medical’s mission is to transform how hospitals and caregivers handle "drugs of concern," or compounds that, when mismanaged, can lead to injuries or even death – the aptly named "never events" that ought to be anathema to healthcare.
Biolase quashes rumors of CEO departure | Personnel Moves
More FDA inspection troubles for Hospira
New communications chief at Covidien | Personnel Moves
Hospira slides after taking $134M charge on infusion pump phase-out
Recall: FDA issues Class 1 recall for Hospira’s GemStar infusion system battery
Hospira recalls contaminated saline solution
Hospira plays musical chairs | Personnel Moves
FDA shakes down Hospira facility in a 3-week inspection
Correction – this article mistakenly suggested that the manufacturing facility in question produces infusion pumps.
Medical device company Hospira (NYSE:HSP) disclosed an FDA inspection of its Rocky Mount, N.C., facility, saying 5 agency inspectors reviewed the facility for 3 weeks and issued a Form 483 warning flagging 20 problems at the plant.
